openPR Logo
Press release

Dengue Vaccines Market In-depth Analysis by Leading Players – Sanofi, Takeda Pharmaceutical

10-10-2018 02:40 PM CET | Health & Medicine

Press release from: CMI Market Research - Pharmaceutical Industry

Dengue Vaccines Industry

Dengue Vaccines Industry

Sanofi Pasteur’s Dengvaxia, is the culmination of over two decades of scientific innovation and collaboration. The vaccine received its first marketing authorization in 2015, in Mexico. Dengvaxia is the world’s first licensed vaccine for prevention of dengue. It is a tetravalent dengue vaccine that prevents the disease from all four dengue viruses in people aged 9 to 45 years. Sanofi launched the world’s first public dengue vaccination program in the Philippines (2016), followed by Brazil. Dengvaxia is approved in 10 endemic countries worldwide, namely, Singapore, Mexico, the Philippines, Paraguay, Brazil, El Salvador, Costa Rica, Indonesia, Peru, and Guatemala. The global dengue vaccines market is thus, expected to expand with growing market approvals.

Download PDF Brochure of Research Report: www.coherentmarketinsights.com/insight/request-pdf/23

India is however taking a precautionary approach in approving this vaccine due to lack of studies among the population in the country. A scientist in India has developed a dengue vaccine that was successfully tested in monkeys. If successful in human trials, this could be a breakthrough invention for prevention of dengue among the populace in the country. Moreover, various philanthropists and global organizations are investing in developing vaccines for malaria and dengue.

Dengue is a mosquito-borne flavivirus debilitating disease with high prevalence in most tropical and sub-tropical regions. Dengue is a painful disease that is also known as ‘break bone’ fever due to the excruciating bone and joint pain associated with it. No therapeutics have been discovered for treatment of the disease caused by four closely related dengue viruses (DEN-1, DEN-2, DEN-3 and DEN-4). Therefore, focus has been mainly on prevention by controlling the vectors being borne. Severe dengue was discovered in the 1950s during dengue epidemics in Philippines and Thailand. The disease has since spread to Asian and Latin America countries and is one of the leading causes of hospitalization and deaths among children and adults in these regions.

Prevalent Scenario in the Global Dengue Vaccines Market

Member states in three of the WHO regions regularly report the annual number of dengue cases. These statistic suggest that the number of dengue cases increased from 2.2 million in 2010 to 3.2 million in 2015. The actual number remains underreported. One recent estimate by Bhatt et al., (also quoted by the WHO) mentions that there are around 390 million dengue cases worldwide each year, with number of cases reported increasing each year. In 2015, 2.35 million cases of dengue were reported in the Americas alone, of which 10,200 cases were diagnosed as severe dengue that led to 1,181 deaths. Dengue is a pertinent health issue affecting people across South America, Europe, and Asia. A large number of dengue outbreaks were reported worldwide in 2015, with over 169,000 cases in the Philippines and over 111,000 suspected cases of dengue in Malaysia. This was a staggering 59.5% and 16% increase respectively in the number of cases compared to that in 2014. The global dengue vaccines market therefore, offers lucrative growth opportunities for vaccine manufacturers.

Request for Customization of Research Report: www.coherentmarketinsights.com/insight/request-customizat...

There are approximately five vaccine candidates under evaluation in clinical trials, including other live-attenuated vaccines, as well as subunit, DNA and purified inactivated vaccine candidates. Also, technological approaches, such as virus-vectored and VLP-based vaccines, are under evaluation in preclinical studies. In September 2016, Takeda announced the beginning of the phase 3 clinical trials of its dengue vaccine – TAK-003 vaccine. This vaccine is also aimed at prevention against all four dengue virus strains.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154
#3200

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dengue Vaccines Market In-depth Analysis by Leading Players – Sanofi, Takeda Pharmaceutical here

News-ID: 1294011 • Views:

More Releases from CMI Market Research - Pharmaceutical Industry

Regenerative Medicine Market growth and trends by 2018-2025 | Depuy Synthes, Inc., Orthofix, Inc., NuVasive, Inc.
Regenerative Medicine Market growth and trends by 2018-2025 | Depuy Synthes, Inc …
Regenerative medicines are medical products or active pharmaceutical ingredients that have the ability to cure or replace organs and tissues organs damaged by various factors such as aging, diseases, trauma, and can also be used to provide stability in congenital disorders. According to findings of various studies, regenerative medicines can also be useful in treating both chronic and acute disorders in terms various context of abnormalities such as cardiovascular diseases,
Precision Medicine Market Revenue Opportunies, Rising at a CAGR of 9.9% and Leading Companies Intomics, ferrer incode, Nanostring Technologies, Inc.Tepnel Pharma Services, Pfizer, Inc., Novartis AG
Precision Medicine Market Revenue Opportunies, Rising at a CAGR of 9.9% and Lead …
Precision medicine is an emerging field, which tailors the treatment according to the individual’s genetic makeup, lifestyle, and environment. The precision medicine have gained popularity due to the positive result obtained by precision medicine in treatment of cancer. It allows the doctors and researchers to predict more accurate treatment and preventive strategies for any particular disease. Precision medicine has also challenged the approach of one drug fits all, as every
Smoking Cessation and Nicotine De-addiction Products Market Revenue Opportunies, Rising at a CAGR of 17.3% and Top players Johnson & Johnson Limited, GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., and Cipla Ltd., Takeda Pharmaceuticals Co.
Smoking Cessation and Nicotine De-addiction Products Market Revenue Opportunies, …
Cigarette packs have been mandatorily carrying a warning stating ‘Smoking is injurious to Health’, while some countries have resorted to even more graphic visuals of victims of smoking. However, this has done precious little to encourage smoking cessation. It is only through awareness created by NGOs and global healthcare organizations that we observe initiatives to stop smoking among the smoking population. Moreover, focus on introducing therapies for smoking cessation has
Regenerative Medicine Market Demand Analysis of Application, Types, Users by Key players includeing Depuy Synthes, Inc., Orthofix, Inc., NuVasive, Inc. and Zimmer Holdings, Inc.
Regenerative Medicine Market Demand Analysis of Application, Types, Users by Key …
Regenerative medicines are medical products or active pharmaceutical ingredients that have the ability to cure or replace organs and tissues organs damaged by various factors such as aging, diseases, trauma, and can also be used to provide stability in congenital disorders. According to findings of various studies, regenerative medicines can also be useful in treating both chronic and acute disorders in terms various context of abnormalities such as cardiovascular diseases,

All 5 Releases


More Releases for Dengue

Key Trend Reshaping the Dengue Treatment Market in 2025: Innovative Drug Deliver …
Which drivers are expected to have the greatest impact on the over the dengue treatment market's growth? The escalation in cases of dengue is projected to stimulate the expansion of the market for dengue treatments. Dengue is a viral infection transmitted by mosquito bites, causing symptoms akin to the flu and can escalate to intense complications if not treated. The escalation is primarily due to progressing urbanization, climate alterations favourable to
Key Dengue Vaccine Market Trend for 2025-2034: Advancements In Dengue Tetravalen …
What Is the Future Outlook for the Dengue Vaccine Market's Size and Growth Rate? In the past few years, the dengue vaccine market has experienced significant growth. From $0.64 billion in 2024, it is projected to reach $0.72 billion in 2025, marking a compound annual growth rate (CAGR) of 12.4%. This notable expansion during the historical period can be credited to factors such as an increase in travel and urbanization trends,
Dengue Vaccine Market : An Detailed Overview
Introduction: Dengue fever is a mosquito-borne viral infection caused by the dengue virus, transmitted primarily through Aedes aegypti and Aedes albopictus mosquitoes. Affecting millions globally each year, dengue has become a significant public health concern, especially in tropical and subtropical regions. The development of dengue vaccines represents a groundbreaking advancement in preventing the disease, reducing its associated healthcare costs, and controlling outbreaks. With increasing awareness and investments in immunization programs, the
Dengue Vaccine Market : An Overview
Introduction: Dengue fever is a mosquito-borne viral infection that has become a significant public health challenge in tropical and subtropical regions. The disease is caused by the dengue virus, which is transmitted primarily by Aedes aegypti mosquitoes. With approximately 390 million infections annually, dengue fever places a substantial burden on healthcare systems and economies worldwide. Efforts to mitigate this burden have led to the development of dengue vaccines, designed to prevent
"Rising Incidence of Dengue Fever Propels Dengue Virus Diagnostic Tests Market T …
According to WHO, dengue affects about 50-100 million people worldwide, annually. It is a vector-borne highly communicable disease. This report discusses the diagnostic tests used to confirm the presence of dengue in one individual. It is true that the growth of the global dengue virus diagnostic tests market is primarily driven by an increase in the incidence of dengue fever, which is a mosquito-borne viral infection that can cause severe flu-like
Dengue Vaccines Market 2021 | Detailed Report
Dengue Vaccines Market Forecasts report provided to identify significant trends, drivers, influence factors in global and regions, agreements, new product launches and acquisitions, Analysis, market drivers, opportunities and challenges, risks in the market, cost and forecasts to 2027. Get Free Sample PDF (including full TOC, Tables and Figures) of Dengue Vaccines Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=4644240 The report provides a comprehensive analysis of company profiles listed below: - Sanofi - Takeda Dengue Vaccines Market Segment by